Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors

(2018) Jay H. Kalin et al.   Nature Communications

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

(2017) Kyriaki Tzogani et al.   ONCOLOGIST

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

(2017) Roberta Mazzone et al.   Clinical Epigenetics

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach

(2016) Elliot M. Epner et al.   EXPERIMENTAL HEMATOLOGY

How do tumor cells respond to HDAC inhibition?

(2016) Andrea Newbold et al.   FEBS Journal

The molecular hallmarks of epigenetic control

(2016) C. David Allis et al.   NATURE REVIEWS GENETICS

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

(2015) H.-Z. Lee et al.   CLINICAL CANCER RESEARCH

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma

(2015) S. P. Iyer et al.   ONCOLOGIST

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy

(2015) Stuart Gallagher et al.   Cancers

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications

(2014) Zhiming Li et al.   International Journal of Biological Sciences

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

(2013) Benjamin E. L. Lauffer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

(2008) Wilko Weichert et al.   LANCET ONCOLOGY